Metcalfe David A 4

4 · NEXTGEN HEALTHCARE, INC. · Filed Nov 2, 2022

Form 4

Period: 2022-11-01

Chief Technology Officer

Transactions

Exercise/Conversion
Common Stock
2022-11-01$14.07/sh+14,744$207,448→ 211,356 total
Exercise/Conversion
Common Stock
2022-11-01$14.20/sh+17,628$250,318→ 196,612 total
Exercise/Conversion
Stock Option (right to buy)
2022-11-01−14,744→ 107,580 total
Exercise: $14.07Exp: 2025-10-31→ Common Stock (14,744 underlying)
Sale
Common Stock
2022-11-01$20.00/sh−32,372$647,485→ 178,984 total
Exercise/Conversion
Stock Option (right to buy)
2022-11-01−17,628→ 100,000 total
Exercise: $14.20Exp: 2024-02-01→ Common Stock (17,628 underlying)

Footnotes (4)

[F1]Pursuant to a 10b5-1(c) plan adopted by the reporting person on March 15, 2022.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request.
[F3]Original grant of 200,000 options granted on 2/1/2016 vested in four equal, annual installments beginning 2/1/2017.
[F4]Original grant of 140,000 options granted on 10/31/2017 vested in four equal, annual installments beginning 10/31/2018.

Documents

1 file